AR056862A1 - 1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion - Google Patents
1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacionInfo
- Publication number
- AR056862A1 AR056862A1 ARP060101206A ARP060101206A AR056862A1 AR 056862 A1 AR056862 A1 AR 056862A1 AR P060101206 A ARP060101206 A AR P060101206A AR P060101206 A ARP060101206 A AR P060101206A AR 056862 A1 AR056862 A1 AR 056862A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkynyl
- aryl
- cycloalkyl
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Son objeto de la presente 1,2-etilendiaminas sustituidas de la formula general (1), en donde los radicales R1 a R15, A, B, L, i, así como X1-X4 están definidos como eh la memoria descriptiva y las reivindicaciones, y su uso para el tratamiento de la enfermedad de Alzheimer (EA) y enfermedades similares. Reivindicacion 1: Compuestos de la formula general (1), en la que A significa arilo- o heteroarilo-, en donde el grupo A junto a los radicales L puede estar eventualmente sustituido con uno o varios átomos de fluor; L, en cada caso independientemente uno de otro, significa hidrogeno, fluor, cloro, bromo, yodo, hidroxi-, carboxi-, formilo-, ciano-, nitro-, F3C-, HF2C-, FH2C-, alquilo C1-6-, alquenilo C2-6-, alquinilo C2-6-, alquil C1-6-S- , alquil C1-6-S-alquilo C1-3-, cicloalquilo C3-7-, cicloalquenilo C3-7-, cicloalquil C3-7-alquilo C1-6-, cicloalquil C3-7-alquenilo C2-6-, cicloalquil C3-7-alquinilo C2-6-, cicloalquenil C3-7-alquilo C1-6-, cicloalquenil C3-7-alquenilo C2-6-, cicloalquenil C3-7-alquinilo C2-6-, arilo-, aril-alquilo C1-6-, aril-alquenilo C2-6-, aril-alquinilo C2-6-, heterociclilo-, heterociclil-alquilo C1-6-, heterociclil-alquenilo C2-6-, heterociclilalquinilo C2-6-, heteroarilo-, heteroaril-alquilo C1-6- , heteroarilalquenilo C2-6-, heteroaril-alquinilo C2-6-, R15-O-, R15-O-alquilo C1-3-, (R14)2N-, (R14)2N-CO-, R14-CO-(R14)N-, (R14)2N-CO-(R14)N-, R14-SO2-(R14)N-, (R14)2N-SO2- o R14-SO2-, en donde los grupos arriba mencionados pueden estar sustituidos, eventualmente de forma independiente uno de otro, con uno o varios radicales seleccionados del grupo consistente en fluor, cloro, bromo, yodo, hidroxi-, oxo-, carboxi-, formilo-, ciano-, nitro-, F3C-, HF2C-, FH2C- hidroxi-alquilo C1-6-, alquilo C1-3-, alcoxi C1-6-, (R14)2N-, (R14)2N-alquilo C1-3-, (R14)2N-CO- y HOSO2-; i significa 0, 1, 2 o 3; B significa un puente de alquileno C1-4, en donde en el caso de un puente de alquileno C3-4 el grupo -CH2 del puente de alquileno C3-4, el cual está unido al grupo A, puede estar reemplazado por -O-, y en donde el puente de alquileno C1-4 puede estar sustituido eventualmente con uno o varios radicales seleccionados del grupo fluor, cloro, bromo, yodo, hidroxi-, oxo-, carboxi-, ciano-, nitro-, F3C-, HF2C-, FH2C-, alquilo C1-4-, alquil C1-6-S-alquilo C1-3-, cicloalquilo C3-7, -cicloalquil C3-7-alquilo C1-3-, heterociclilo-, heterociclil-alquilo C1-3-, arilo-, aril-alquilo C1-3-, heteroarilo-, heteroaril-alquilo C1-3-, R15-O-, (R14)2N-SO2-, (R14)2N-; (R14)2N-alquilo C1-3-, (R14)2N-CO-, R14-SO2-, R14-CO-(R14)N-, R14-SO2(R14)N-, (R14)2N-SO2-, R14-CO- y en donde dos radicales alquilo C1-4, unidos al mismo átomo de carbono del puente de alquileno C1-4, pueden estar unidos entre sí con formacion de un grupo cicloalquilo C3-7, y en donde los radicales arriba mencionados y el grupo cicloalquilo C3-7 configurado a partir de los radicales alquilo C1-4, eventualmente de forma independiente uno de otro, pueden estar sustituidos con uno o varios radicales seleccionados del grupo consistente en fluor, cloro, bromo, yodo, hidroxi-, oxo-, carboxi-, formilo-, ciano-, nitro-, F3C-, HF2C-, FH2C-alquilo C1-3-, alcoxi C1-3-, R15-O-alquilo C1-3-, R14-CO(R14)N-, R14- SO2(R14)N-, (R14)2N-, (R14)2N-alquilo C1-3-, (R14)2N-CO-, (R14)2N-SO2- y HOSO2-; R1 significa hidrogeno, alquilo C1-6-, alquenilo C2-6-, alquinilo C2-6-, cicloalquilo C3-7-, cicloalquil C3-7-alquilo C1-6-, cicloalquil C3-7-alquenilo C2-6-, cicloalquil C3-7-alquinilo C2-6-, cicloalquenilo C3-7-, cicloalquenil C3-7-alquilo C1-6-, cicloalquenil C3-7-alquenilo C2-6-, cicloalquenil C3-7-alquinilo C2-6-, arilo-, aril-alquilo C1-6-, aril-alquenilo C2-6-, arilalquinilo C2-6-, heterociclilo-, heterociclil-alquilo C1-6-, heterociclil alquenilo C2-6-, heterociclil-alquinilo C2-6-, heteroarilo-, heteroarilalquilo C1-6-, heteroaril-alquenilo C2-6- o heteroaril-alquinilo C2-6-, en donde los radicales arriba mencionados pueden estar sustituidos, eventualmente de forma independiente uno de otro, con uno o varios radicales seleccionados del grupo consistente en fluor, cloro, bromo, yodo, hidroxi-, oxo-, carboxi-, formilo-, ciano-, nitro-, F3C-, HF2C-, FH2C-, alquilo C1-3-, alcoxi C1-3-, hidroxi-alquilo C1-6-, (R14)2N-, (R14)2N-alquilo C1-3-, (R14)2N-CO-(R14)2N-SO2-, R14-CO-(R14)N-, y HOSO2-; X1 significa nitrogeno o C(R10); X2, X3, X4, en cada caso independientemente uno de otro, significan nitrogeno o C(R11), con la condicion de que 0, 1, 2 o 3 de los grupos X1, X2, X3 y X4 puedan ser nitrogeno; R2 significa alquilo C1-6-, alquenilo C2-6-, alquinilo C2-6-, R15-O-alquilo C1-3-, alquil C1-6-S-alquilo C1-3-, cicloalquilo C3-7-, cicloalquil C3-7-alquinilo C2-6-, cicloalquenilo C3-7-, cicloalquenil C3-7-alquilo C1-6-, cicloalquenil C3-7-alquenilo C2-6-, cicloalquenil C3-7-alquinilo C2-6-, heterociclilo-, cicloalquil C3-7-alquilo C1-3-, heterociclil-alquilo C1-3-, cicloalquil C3-7-alquenilo C2-3-, heterociclil-alquenilo C2-3-, heterociclil-alquinilo C2-3-, arilo-, heteroarilo-, aril-alquilo C1-3-, heteroarilalquilo C1-3-, aril-alquenilo C2-3-, aril-alquinilo C2-3-, heteroarilalquenilo C2-3- o heteroaril-alquinilo C2-3-, en donde los radicales arriba mencionados, eventualmente de forma independiente uno de otro, pueden estar sustituidos con uno o varios radicales seleccionados del grupo consistente en fluor, cloro, bromo, yodo, F3C-, HF2C-, FH2C- hidroxi-, oxo-, carboxi-, formilo-, ciano- , nitro-, (R14)2N-, (R14)2N-alquilo C1-3, HOSO2-, alquilo C1-3, alquil C1-6-S-alquilo C1-3, (R14)2N-SO2-, R14-CO(R14)N-, R14-SO2(R14)N-, (R14)2N-CO-, R15-O- y R15-O-alquilo C1-3-; R3, R4, en cada caso independientemente uno de otro, significan hidrogeno, alquilo C1-4-, fluor, F3C-, HF2C- o FH2C-; R5, R7, en cada caso independientemente uno de otro, significa hidrogeno, alquilo C1-6-, alquenilo C2-6-, alquinilo C2-6-, cicloalquilo C3-7-, heterociclilo-, cicloalquil C3-7-alquilo C1-3-, cicloalquil C3-7-alquinilo C2-6-, heterociclil-alquilo C1-3-, cicloalquil C3-7-alquenilo C2-4-, heterociclilalquenilo C2-4-, heterociclil-alquinilo C2-4-, cicloalquenilo C3-7-, cicloalquenil C3-7-alquilo C1-6-, cicloalquenil C3-7-alquenilo C2-6-, cicloalquenil C3-7-alquinilo C2-6-, arilo-, heteroarilo-, aril-alquilo heteroaril-alquilo C1-3-, aril-alquenilo C2-3-, heteroaril-alquenilo C2-3-, aril-alquinilo C2-3- o heteroaril-alquinilo C2-3-, en donde los radicales arriba mencionados, eventualmente de forma independiente uno de otro, pueden estar sustituidos con uno o varios radicales seleccionados del grupo consistente en fluor, cloro, bromo, yodo, hidroxi-, oxo-, carboxi-, formilo-, ciano, nitro-, alquilo C1-3-, R15-O-, alquil C1-3-S-, arilo-, heteroarilo-, heteroaril-alquilo C1-3-, aril-alquilo C1-6-, R14-CO-(R14)N-, R14-SO2-(R14)N-, (R14)2N-SO2-, (R14)2N-, (R14)2N-alquilo C1-3, (R14)2N-CO- y HOSO2-; R6, R9 significan, en cada caso independientemente uno de otro, hidrogeno, alquilo C1-6-, alcoxi C1-6-alquilo C1-3-, cicloalquilo C3-7-, cicloalquil C3-7-alquilo C1-3-, alquenilo C2-6-, heterociclil-alquilo C1-3-, heteroarilo-, heteroaril-alquilo C1-3, o alquinilo C2-6-, en donde los radicales arriba mencionados pueden estar sustituidos, eventualmente de forma independiente uno de otro, con uno o varios radicales seleccionados del grupo consistente en fluor, cloro, bromo, yodo, ciano-, alquilo C1-3-, alcoxi C1-6-; R8 significa hidrogeno, alquilo C1-6-, alquenilo C2-6-, alquinilo C2-6-, cicloalquilo C3-7-, cicloalquil C3-7-alquilo C1-3-, cicloalquil C3-7-alquenilo C2-4-, cicloalquil C3-7-alquinilo C2-4-, cicloalquenilo C3-7-, cicloalquenil C-3-7-alquilo C1-6, cicloalquenil C3-7-alquenilo C2-6, cicloalquenil C3-7-alquinilo-C2-6-, heterociclilo-, heterociclil-alquilo C1-3-, heterociclil-alquenilo C2-4-, heterociclil-alquinilo C2-4-, arilo-, aril-alquilo C1-3-, aril-alquenilo C2-4, - aril-alquinilo C2-4-, heteroarilo-, heteroaril-alquilo C1- 3-, heteroarilalquenilo C2-4- o heteroaril-alquinilo C2-4-, en donde los radicales arriba mencionados, eventualmente de forma independiente uno de otro, pueden estar sustituidos con uno o varios radicales seleccionados del grupo consistente en fluor, cloro, bromo, yodo, hidroxi-, oxo-, carboxi-, formilo-, ciano-, nitro-, alquilo C1-3-, heterociclilo-, heterociclil-alquilo C1-3-, R15-O-, R15-O-alquilo C1-3-, R15-S-, R15-S-alquilo C1-3-, arilo-, heteroarilo-, heteroarilalquilo C1-3-, aril- alquilo C1-6-, (R14)2N-, (R14)2N-alquilo C1-3-, (R14)2N-CO-, (R14)2N-CO-N(R14)-, (R14)2N-SO2- y HOSO2-; R10 significa hidrogeno, fluor, cloro, bromo, yodo, ciano-, alquilo C1-6-, alquenilo C2-6-, alquinilo C2-6-, cicloalquilo C3-7-, cicloalquil C3-7- alquilo C1-6-, cicloalquil C3-7-alquinilo C2-6-, heterociclilo-, heterociclil-alquilo C1-6-, heterociclil-alquenilo C2-6-, heterociclil-alquinilo C2-6-, cicloalquil C3-7-alquenilo C2-6-, heterociclil-alquenilo C2-4-, cicloalquenilo C3-7-, cicloalquenil C3-7-alquilo C1-6-, cicloalquenil C3-7-alquenilo C2-6, cicloalquenil C3-7-alquinilo C2-6-, arilo:, aril-alquilo C1-6-, heteroarilo-, heteroaril-alquilo C1-6-, aril-alquenilo C2-6-, heteroaril-alquenilo C2-6-, aril-alquinilo C2-6- o heteroaril-alquinilo C2-6-, R15-O-, R15-O-alquilo C1-3-, R12-SO2-(R13)N- o R12-CO-(R13)N-, en donde los grupos arriba mencionados pueden estar sustituidos, eventualmente de forma independiente uno de otro, con uno o varios radicales seleccionados del grupo consistente en fluor, cloro, bromo, yodo, hidroxi-, oxo-, carboxi-, formilo-, ciano-, nitro-, alquilo C1-6-, alquenilo C2-6, alquinilo C2-6, alquil C1-6-S-, alquil C1-6-S-alquilo C1-3-, cicloalquilo C3-7-, cicloalquil C3-7-alquilo C1-6-, arilo-, aril-alquilo C1-6-, heterociclilo-, heterociclil-alquilo C1-6-, heteroarilo-, heteroaril-alquilo C1-6-, R15-O-, R15-O-CO-, R15-CO-, R15-O-CO-(R14)N-, (R14)2N-CO-O-, R15-O-alquilo C1-3-, (R14)2N-, (R14)2N-CO-, R14-CO-(R14)N-, (R14)2N-CO- (R14)N-, (R14)2N-SO2-, (R14)2N-SO2-(R14)N-, R14SO2, F3C-, HF2C-, FH2C, F3C-O-, HF2CO-, FH2C-O y R14-SO2-(R14)N-; R11, en cada independientemente uno de otro, signifi
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05006939 | 2005-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056862A1 true AR056862A1 (es) | 2007-10-31 |
Family
ID=36545049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101206A AR056862A1 (es) | 2005-03-30 | 2006-03-29 | 1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion |
Country Status (7)
Country | Link |
---|---|
US (3) | US7713961B2 (es) |
EP (1) | EP1866034A1 (es) |
JP (1) | JP2008534541A (es) |
AR (1) | AR056862A1 (es) |
CA (1) | CA2603404A1 (es) |
TW (1) | TW200716152A (es) |
WO (1) | WO2006103038A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2603404A1 (en) * | 2005-03-30 | 2006-10-05 | Boehringer Ingelheim International Gmbh | Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture |
CA2617294A1 (en) * | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii |
WO2007017510A2 (de) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Isophthalsäurediamide zur behandlung der alzheimer erkrankung |
CA2618019A1 (en) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Compounds for the treatment of alzheimer's disease |
CA2618481A1 (en) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Compounds for treating alzheimer's disease |
CA2618013A1 (en) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Beta-secretase inhibitors for use in the treatment of alzheimer's disease |
EP2349308A4 (en) | 2008-10-10 | 2012-09-12 | Purdue Research Foundation | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
WO2010059953A1 (en) | 2008-11-20 | 2010-05-27 | Purdue Research Foundation | Quinazoline inhibitors of bace 1 and methods of using |
US8859590B2 (en) | 2008-12-05 | 2014-10-14 | Purdue Research Foundation | Inhibitors of BACE1 and methods for treating Alzheimer's disease |
WO2011044057A1 (en) * | 2009-10-05 | 2011-04-14 | Comentis, Inc. | Sulfonamido pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof |
US20140066488A1 (en) * | 2012-08-30 | 2014-03-06 | Purdue Research Foundation | Inhibitors of Memapsin 2 Cleavage for the Treatment of Alzheimer's Disease |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ184194A3 (en) | 1993-08-09 | 1995-03-15 | Lilly Co Eli | Aspartylprotease inhibitor and method of identifying thereof |
US7087399B1 (en) | 1999-05-13 | 2006-08-08 | Scios, Inc. | β-secretase and modulation of β-secretase activity |
US6545127B1 (en) | 1999-06-28 | 2003-04-08 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
US20050130941A1 (en) * | 2001-06-08 | 2005-06-16 | Heinrich Schostarez | Methods of treating alzheimer's disease |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
WO2003057721A2 (en) * | 2002-01-04 | 2003-07-17 | Elan Pharmaceuticals, Inc. | Substituted amino carboxamides for the treatment of alzheimer's disease |
JP2006501282A (ja) * | 2002-09-27 | 2006-01-12 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病治療のための化合物 |
EP1562897B1 (en) * | 2002-11-12 | 2009-09-16 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease |
US20050090449A1 (en) | 2003-05-13 | 2005-04-28 | Boehringer Ingelheim International Gmbh | Novel statine derivatives for the treatment of Alzheimer's disease |
EP1641748B1 (en) * | 2003-06-30 | 2013-08-28 | Merck Sharp & Dohme Corp. | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease |
WO2005110422A2 (en) | 2004-05-19 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Treatment of diseases associated with altered level of amyloid beta peptides |
WO2005113582A1 (en) | 2004-05-22 | 2005-12-01 | Boehringer Ingelheim International Gmbh | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease |
WO2006050862A1 (en) | 2004-11-10 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Statine derivatives for the treatment of alzheimer's disease |
WO2006050861A2 (en) | 2004-11-10 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Statine derivatives for the treatment of alzheimer's disease |
CA2603404A1 (en) * | 2005-03-30 | 2006-10-05 | Boehringer Ingelheim International Gmbh | Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture |
CA2617294A1 (en) | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii |
CA2618019A1 (en) | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Compounds for the treatment of alzheimer's disease |
-
2006
- 2006-03-27 CA CA002603404A patent/CA2603404A1/en not_active Abandoned
- 2006-03-27 EP EP06723747A patent/EP1866034A1/en not_active Withdrawn
- 2006-03-27 JP JP2008503415A patent/JP2008534541A/ja active Pending
- 2006-03-27 WO PCT/EP2006/002769 patent/WO2006103038A1/en not_active Application Discontinuation
- 2006-03-29 TW TW095110860A patent/TW200716152A/zh unknown
- 2006-03-29 AR ARP060101206A patent/AR056862A1/es not_active Application Discontinuation
- 2006-03-30 US US11/278,059 patent/US7713961B2/en active Active
-
2009
- 2009-07-29 US US12/511,474 patent/US20090325940A1/en not_active Abandoned
-
2010
- 2010-04-13 US US12/759,167 patent/US20100204160A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20060223759A1 (en) | 2006-10-05 |
WO2006103038A1 (en) | 2006-10-05 |
EP1866034A1 (en) | 2007-12-19 |
JP2008534541A (ja) | 2008-08-28 |
CA2603404A1 (en) | 2006-10-05 |
US7713961B2 (en) | 2010-05-11 |
US20090325940A1 (en) | 2009-12-31 |
US20100204160A1 (en) | 2010-08-12 |
TW200716152A (en) | 2007-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056862A1 (es) | 1,2-etilendiaminas sustituidas, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion | |
UY33961A (es) | Compuestos de bis(fuoroalquil)-1,4-benziodiazepinona | |
EA200700909A1 (ru) | Азаиндолкарбоксамиды | |
CO6290658A2 (es) | Derivados de azetidina y ciclobutano como inhibidores de jack | |
HN2012000889A (es) | Derivados de la cromenona con actividad anti-tumoral | |
AR056560A1 (es) | Pirrolopiridinonas como moduladores cb1 | |
ECSP10010209A (es) | Agonistas novedosos de los receptores de glucocorticoides | |
EA201171098A1 (ru) | 8-замещенные хинолины и родственные аналоги в качестве модуляторов сиртуина | |
AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
PA8604201A1 (es) | Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades | |
SV2006002098A (es) | Compuestos de morfolina sustituida para el tratamiento de trastornos del sistema nervioso central ref. pc32250a | |
BRPI0515546A (pt) | compostos para inflamação e usos imune-relacionados | |
AR051326A1 (es) | Pirazolobenzodiazepinas disustituidas | |
AR077413A1 (es) | Derivados piridin-4-ilo | |
CO6321241A2 (es) | Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp) | |
UY28150A1 (es) | Agentes terapeuticos | |
CY1111733T1 (el) | Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri | |
PA8627001A1 (es) | Compuestos para el tratamiento de enfermedades | |
AR090712A1 (es) | Agentes para tratar trastornos que implican la modulacion de receptores de rianodina | |
SE0502254L (sv) | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission | |
PA8779101A1 (es) | "compuestos tricíclicos como inhibidores de metaloproteinasas matriciales" | |
AR078142A1 (es) | Compuestos inhibidores heteroarilicos biciclicos de pde4, las composiciones farmaceuticas que los contienen y el uso de los mismos para la preparacion de medicamentos. | |
EA201000362A1 (ru) | Производные 1,3-дигидроизоиндола | |
CR8636A (es) | Compuestos utiles para el tratamiento de enfermedades | |
SE0401465D0 (sv) | New substituted piperdines as modulators of dopamine neurotransmission |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |